Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.71 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | TARS1 | P26639 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13888558 | 0.97 | DHFR (0.93) | DHFRMAP4K4DCPSHRH4ADORA2A | |
| SCHEMBL8512974 | 0.87 | DHFR (1.00) | DHFRMAP4K4DCPSHRH4TARS1 | |
| SCHEMBL5507908 | 0.84 | DHFR (0.75) | DHFRMAP4K4DCPSHRH4ADORA2A | |
| SCHEMBL15587285 | 0.83 | MAP4K4 (1.00) | DHFRMAP4K4JAK2 | |
| SCHEMBL19876625 | 0.83 | DHFR (0.71) | DHFRMAP4K4HRH4JAK2TARS1 | |
| SCHEMBL8512311 | 0.81 | DHFR (1.00) | DHFRMAP4K4DCPSHRH4ADORA2A | |
| SCHEMBL4516307 | 0.79 | DHFR (0.73) | DHFRMAP4K4DCPSADORA2A | |
| SCHEMBL4528809 | 0.79 | DHFR (0.65) | DHFRMAP4K4HRH4 | |
| SCHEMBL29375878 | 0.78 | DCPS (1.00) | DHFRDCPSADORA2ANUDT1 | |
| SCHEMBL269636 | 0.78 | DCPS (1.00) | DHFRDCPSADORA2ANUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835445-B2 | Dihydrofolate reductase inhibitors | TRIUS THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | DHFR, DPYD, DHODH | DHFR 1/4885MAP4K4 4343/4885DCPS 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.